Trending...
- USA Med Bed Helping Home Care Patients with Refurbished Hill Rom Hospital Beds
- CAPHRA warns Southeast Asia not to repeat Australia's nicotine policy failure
- KRE PRIME Launches Adaptive Convertible Jumpsuit
* A GLP ~ A new study presented at the Alzheimer's Association International Conference® (AAIC®) 2024 has revealed promising results for a drug that may slow cognitive decline in individuals with Alzheimer's disease. The Phase 2b clinical trial data, reported by researchers today in Philadelphia and online, suggests that a glucagon-like peptide-1 (GLP-1) drug can protect the brain and potentially reduce cognitive decline.
GLP-1 receptor agonists are drugs that mimic the natural hormone glucagon-like peptide released by the stomach after eating. These drugs are commonly used to manage diabetes, promote weight loss, and lower the risk of heart disease, stroke, and kidney disease. Previous research in animal models of Alzheimer's disease has shown that GLP-1 receptor agonists may have neuroprotective effects, reduce early forms of amyloid (a protein associated with Alzheimer's), normalize glucose processing in the brain, and improve memory and learning. The specific GLP-1 receptor agonist studied in this trial was liraglutide, manufactured by Novo Nordisk.
The new research presented at AAIC 2024 suggests that liraglutide may have a protective effect on the brains of individuals with mild Alzheimer's disease. After one year of treatment, those who received liraglutide showed an 18% reduction in cognitive decline compared to those who received a placebo. This was measured by slowing the shrinking of key areas of the brain responsible for memory, learning, language, and decision-making.
More on The PennZone
Maria C. Carrillo, Ph.D., chief science officer and medical affairs lead for the Alzheimer's Association, expressed hope for these findings: "We are in an era of unprecedented promise with new treatments in development that may slow or even prevent cognitive decline due to Alzheimer's disease." She also noted that repurposing drugs already approved for other conditions has advantages such as providing data from previous research and practical use.
The Alzheimer's Association has invested over $82 million in the Part the Cloud research grants program, which has supported 68 clinical trials targeting various compounds, including repurposed drugs, to address different aspects of the disease.
The ELAD trial, led by Prof. Paul Edison, M.D., Ph.D., from Imperial College London, included 204 patients with mild Alzheimer's disease from 24 clinics in the United Kingdom. The participants were randomly assigned to receive either a daily subcutaneous injection of up to 1.8 mg of liraglutide or a placebo for one year. Before and after the study, all patients underwent magnetic resonance imaging (MRI) to evaluate brain structure and volumes, glucose metabolism PET scans, and detailed memory testing.
More on The PennZone
While the primary endpoint of change in cerebral glucose metabolic rate was not met, the secondary endpoint of change in clinical and cognitive measures showed significant benefit for those who received liraglutide. Additionally, an exploratory endpoint of brain volume also showed statistically significant improvement.
Dr. Edison explained that the slower loss of brain volume seen in those who received liraglutide suggests that the drug may protect the brain similarly to how statins protect the heart. He also noted that further research is needed to fully understand how liraglutide works but suggested that it may reduce inflammation in the brain, lower insulin resistance, and improve communication between nerve cells.
In terms of cognitive function, researchers found that those who received liraglutide had an 18% slower decline compared to those who received a placebo. This was measured by a composite score of 18 different tests assessing memory, comprehension, language, and spatial orientation.
Overall, this study provides hope for potential new treatments for Alzheimer's disease and highlights the importance of repurposing drugs already approved for other conditions. Further research is needed to fully understand how liraglutide works and its potential as a treatment for Alzheimer's disease.
GLP-1 receptor agonists are drugs that mimic the natural hormone glucagon-like peptide released by the stomach after eating. These drugs are commonly used to manage diabetes, promote weight loss, and lower the risk of heart disease, stroke, and kidney disease. Previous research in animal models of Alzheimer's disease has shown that GLP-1 receptor agonists may have neuroprotective effects, reduce early forms of amyloid (a protein associated with Alzheimer's), normalize glucose processing in the brain, and improve memory and learning. The specific GLP-1 receptor agonist studied in this trial was liraglutide, manufactured by Novo Nordisk.
The new research presented at AAIC 2024 suggests that liraglutide may have a protective effect on the brains of individuals with mild Alzheimer's disease. After one year of treatment, those who received liraglutide showed an 18% reduction in cognitive decline compared to those who received a placebo. This was measured by slowing the shrinking of key areas of the brain responsible for memory, learning, language, and decision-making.
More on The PennZone
- Zenylitics Announces Leadership Transition to Continue Accelerated Growth
- Wellness Technology Distributor Helping People Set Up Wellness Center Businesses
- Christian Apocalyptic Thriller Explores Biblical Prophecy, Global Technology, & the Rise of the Ant
- Turnstone Creative Expands Leadership Team with Addition of Marketing Manager
- The Hidden Price Of Lost Property In UK Schools
Maria C. Carrillo, Ph.D., chief science officer and medical affairs lead for the Alzheimer's Association, expressed hope for these findings: "We are in an era of unprecedented promise with new treatments in development that may slow or even prevent cognitive decline due to Alzheimer's disease." She also noted that repurposing drugs already approved for other conditions has advantages such as providing data from previous research and practical use.
The Alzheimer's Association has invested over $82 million in the Part the Cloud research grants program, which has supported 68 clinical trials targeting various compounds, including repurposed drugs, to address different aspects of the disease.
The ELAD trial, led by Prof. Paul Edison, M.D., Ph.D., from Imperial College London, included 204 patients with mild Alzheimer's disease from 24 clinics in the United Kingdom. The participants were randomly assigned to receive either a daily subcutaneous injection of up to 1.8 mg of liraglutide or a placebo for one year. Before and after the study, all patients underwent magnetic resonance imaging (MRI) to evaluate brain structure and volumes, glucose metabolism PET scans, and detailed memory testing.
More on The PennZone
- Milton Collier, CEO & President of Freight Broker 911, Eliminates the #1 Barrier to Entry in Logistics: Announces 100% Free Freight Broker Training
- FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
- AI Velocity Trading Launches Institutional-Grade Algorithmic Engine for Retail Investors
- America's Workforce Solution, LLC Assessed "Awardable" for Department of War work in the CDAO's Tradewinds Solutions Marketplace
- Speaker and Certified Coach Syrena N. Williams Debuts Powerful New Book on Healing, Identity, and Wholeness
While the primary endpoint of change in cerebral glucose metabolic rate was not met, the secondary endpoint of change in clinical and cognitive measures showed significant benefit for those who received liraglutide. Additionally, an exploratory endpoint of brain volume also showed statistically significant improvement.
Dr. Edison explained that the slower loss of brain volume seen in those who received liraglutide suggests that the drug may protect the brain similarly to how statins protect the heart. He also noted that further research is needed to fully understand how liraglutide works but suggested that it may reduce inflammation in the brain, lower insulin resistance, and improve communication between nerve cells.
In terms of cognitive function, researchers found that those who received liraglutide had an 18% slower decline compared to those who received a placebo. This was measured by a composite score of 18 different tests assessing memory, comprehension, language, and spatial orientation.
Overall, this study provides hope for potential new treatments for Alzheimer's disease and highlights the importance of repurposing drugs already approved for other conditions. Further research is needed to fully understand how liraglutide works and its potential as a treatment for Alzheimer's disease.
Filed Under: Business
0 Comments
Latest on The PennZone
- Color Card Administrator Highlights Growing Enterprise Demand for Workflow Orchestration in Enterprise Business Card Governance
- Tennessee Laws Lead with Psychotropic Drug Testing in Mass Shooting Cases and Comprehensive Reporting: CCHR Urges Nationwide Adoption
- Curious About Mensa? DFW Event Offers a 1-Day Immersion
- Morphy's will breeze into summer with a June 10-11 Fine & Decorative Arts auction featuring nearly 1,200 high-quality lots
- L-Tron to Exhibit at American Association for Motor Vehicle Administrators Region 1 Conference
- Buzzblender Announces Launch of Simple Hotel Mode for Android and Upcoming Video Wall Support for Samsung Professional Displays
- How Strategic WooCommerce Development and Digital Marketing Helped a Fashion Ecommerce Business Increase Revenue by 3X
- Burkentine Builders Breaks Ground For Two New Communities
- VIV Welcomes Residents to St. Petersburg's EDGE District
- Evocative Joins the Independent Data Centre Network (IDCN) as Primary USA Operator
- Philadelphia Scientist Roohid Parast Advances IBD Research at Johnson & Johnson
- Medical Experts Highlight the Importance of Second Opinions in Death Investigations
- Joseph Nybyk aka Neibich of Gilbert, Arizona
- Omnitronics Unveils 100% Software omniGateDMR and omniGateP25 RoIP Gateways
- KRE PRIME Launches Adaptive Convertible Jumpsuit
- USA Med Bed Helping Home Care Patients with Refurbished Hill Rom Hospital Beds
- Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
- CAPHRA warns Southeast Asia not to repeat Australia's nicotine policy failure
- Milo3D.ai Launches Free AI 3D Model Generator That Turns Text and Images Into Game-Ready 3D Assets in Seconds
- UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA